{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:06:51Z","timestamp":1772572011593,"version":"3.50.1"},"reference-count":23,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.2217\/fon-2019-0762","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T14:09:22Z","timestamp":1579270162000},"page":"11-19","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma"],"prefix":"10.1080","volume":"16","author":[{"given":"Michael R","family":"Migden","sequence":"first","affiliation":[{"name":"Departments of Dermatology & Head & Neck Surgery,University of Texas, MD Anderson Cancer Center, Houston, TX77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-5069","authenticated-orcid":false,"given":"Sunandana","family":"Chandra","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Rabinowits","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Miami Cancer Institute\/Baptist Health South Florida, Miami, FL33176, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-I","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigar","family":"Desai","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Seluzhytsky","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medha","family":"Sasane","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, NJ08807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Campanelli","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morganna L","family":"Freeman","sequence":"additional","affiliation":[{"name":"Formerly of Department of Medical Oncology & Therapeutics Research,City of Hope Comprehensive Cancer Center, Duarte, CA91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherrif F","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Dermatologic Surgery, University of Rochester Medical Center, Rochester, NY14642, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil I","family":"Khushalani","sequence":"additional","affiliation":[{"name":"Department of Cutaneous Oncology,Moffitt Cancer Center, Tampa, FL33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andria","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Dermatology,Brigham & Women\u2019s Hospital, Harvard Medical School, Boston, MA02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1187"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10830.x"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000478"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.110"},{"key":"e_1_3_5_7_1","unstructured":"NCCN . National Comprehensive Cancer Network clinical practice guidelines in oncology: squamous cell skin cancer (version 2.2019) (2019). www.nccn.org\/professionals\/physician_gls\/pdf\/squamous.pdf"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.075"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e21033"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.048"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0665"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9526"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.6015"},{"key":"e_1_3_5_16_1","unstructured":"Regeneron PharmaceuticalsInc . LIBTAYO\u00ae (cemiplimab-rwlc) full prescribing information (2019). www.regeneron.com\/sites\/default\/files\/Libtayo_FPI.pdf"},{"key":"e_1_3_5_17_1","unstructured":"European Medicines Agency . LIBTAYO\u00ae EPAR (2019). www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libtayo"},{"key":"e_1_3_5_18_1","unstructured":"Government of Canada . LIBTAYO\u00ae \u2013 notice of compliance with conditions \u2013 qualifying notice (2019). www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions\/libtayo-notice-compliance-conditions-218718.html"},{"key":"e_1_3_5_19_1","unstructured":"ANVISA . [GGMED restructuring] (2019). http:\/\/portal.anvisa.gov.br\/informacoes-tecnicas13?p_p_id=101_INSTANCE_WvKKx2fhdjM2&p_p_col_id=column-2&p_p_col_pos=1&p_p_col_count=2&_101_INSTANCE_WvKKx2fhdjM2_groupId=219201&_101_INSTANCE_WvKKx2fhdjM2_urlTitle=libtayo-anvisa-aprova-novo-produto-biologico-para-tratamento-de-cancer-de-pele&_101_INSTANCE_WvKKx2fhdjM2_struts_action=%2Fasset_publisher%2Fview_content&_101_INSTANCE_WvKKx2fhdjM2_assetEntryId=5434438&_101_INSTANCE_WvKKx2fhdjM2_type=content"},{"key":"e_1_3_5_20_1","unstructured":"NICE . Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (2019). www.nice.org.uk\/guidance\/gid-ta10304\/documents\/final-appraisal-determination-document"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479018764662"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001755"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2019.100188"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f167"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:01Z","timestamp":1719125161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.2217\/fon-2019-0762"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0762","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}